- Previous Close
115.00 - Open
115.50 - Bid 110.00 x --
- Ask 115.00 x --
- Day's Range
110.00 - 116.75 - 52 Week Range
95.00 - 151.00 - Volume
110,524 - Avg. Volume
106,747 - Market Cap (intraday)
97.2M - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
-- - EPS (TTM)
-0.03 - Earnings Date May 2, 2025 - May 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
199.40
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. The company offers DXRX, a diagnostic commercialisation platform for precision medicine that integrates multiple pipelines of diagnostic testing data from network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which delivers an actionable alert of a testing behavior for making treatment decisions; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and the physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports. In addition, the company offers professional services, such as market landscape, implementation, and consulting services. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
www.diaceutics.com184
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DXRX.L
View MorePerformance Overview: DXRX.L
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DXRX.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DXRX.L
View MoreValuation Measures
Market Cap
95.09M
Enterprise Value
79.47M
Trailing P/E
--
Forward P/E
0.78
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.64
Price/Book (mrq)
2.45
Enterprise Value/Revenue
3.05
Enterprise Value/EBITDA
55.97
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.90%
Return on Assets (ttm)
-6.06%
Return on Equity (ttm)
-7.13%
Revenue (ttm)
26.09M
Net Income Avi to Common (ttm)
-2.85M
Diluted EPS (ttm)
-0.03
Balance Sheet and Cash Flow
Total Cash (mrq)
16.75M
Total Debt/Equity (mrq)
2.93%
Levered Free Cash Flow (ttm)
1.41M